AveXis

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
AveXis
IndustryBiotechnology, Pharmaceutical
Headquarters,
ParentNovartis
Websitewww.avexis.com

AveXis is a biotechnology company whose drug pipeline includes gene therapy preparations for rare neurological genetic disorders, the most advanced one being onasemnogene abeparvovec (AVXS-101) for spinal muscular atrophy (SMA)[1], which was approved in May 2019.[2] AveXis was acquired by Novartis in 2018.[3][4][5][6][7][8][9]

References[edit]

  1. ^ Kaiser, Kaiser (1 November 2017). "Gene therapy's new hope: A neuron-targeting virus is saving infant lives". Science. Retrieved 10 January 2018.
  2. ^ Template:Cite Reuters (2019-05-25). "$2.1m Novartis gene therapy to become world's most expensive drug". The Guardian. ISSN 0261-3077. Retrieved 2019-05-25.
  3. ^ Herper, Mathew (19 December 2018). "A Year In, Novartis' Boss Faces The World". Forbes. Retrieved 10 January 2018.
  4. ^ Delclaux, Alberto (9 April 2018). "Novartis Bets $8.7 Billion on Gene-Therapy Company". The Wall Street Journal. Retrieved 10 January 2018.
  5. ^ Rose, Marla (9 April 2018). "Gene-therapy company with research ties to Columbus sold to Novartis for $8.7 billion". The Columbus Dispatch. Retrieved 10 January 2018.
  6. ^ Miller, John (9 April 2018). "Novartis bets big on gene therapy with $8.7 billion AveXis deal". Reuters. Retrieved 10 January 2018.
  7. ^ Kresge, Naomi (9 April 2018). "Novartis Wager on AveXis Shows Rare Diseases Command Mega Prices". Bloomberg News. Retrieved 10 January 2018.
  8. ^ Kresge, Naomi (9 April 2018). "Novartis CEO Spurs Rare-Disease Shift With $8.7 Billion Deal". Bloomberg News. Retrieved 10 January 2018.
  9. ^ Woodyard, Chris (9 April 2018). "Novartis buying AveXis for $8.7B in big gene therapy bet". USA Today. Retrieved 10 January 2018.